Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069

NCT01989520 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Uncontrolled and Persistent Asthma

Interventions

DRUG: Phase IIb formulation
DRUG: Putative phase III formulation
DRUG: Slow dissolution variant 1
DRUG: Slow dissolution variant 2
DRUG: Test treatment E

Sponsor

AstraZeneca